Dr. Niharika R. Samala, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 203
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
IN license 01073844A -
Internal Medicine Physician
IN license 01073844A · MI license 4301092135
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Indiana University Health Bloomington Hospital Bloomington, IN
- Indiana University Health Ball Memorial Hospital Muncie, IN
- Indiana University Health Arnett Hospital Lafayette, IN
- Indiana University Health North Hospital Carmel, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 203
- Services billed
- 314
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 96 | 86 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 39 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 38 | 38 |
| Measurement of liver stiffness | 32 | 27 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 23 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | 20 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Royal Oak, MI | 91 |
| Pantoprazole Sodium Other prescribers in Royal Oak, MI | 85 |
| Furosemide Other prescribers in Royal Oak, MI | 82 |
| Carvedilol Other prescribers in Royal Oak, MI | 69 |
| Ursodiol Other prescribers in Royal Oak, MI | 61 |
| Lactulose Other prescribers in Royal Oak, MI | 57 |
| Xifaxan (rifaximin) Other prescribers in Royal Oak, MI | 43 |
| Omeprazole Other prescribers in Royal Oak, MI | 25 |
| Entecavir | 17 |
| Hydroxyzine Hcl Other prescribers in Royal Oak, MI | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $2,847 in total to this clinician.
| Novo Nordisk Inc | $2,748 |
|---|---|
| Madrigal Pharmaceuticals | $99.75 |
| Consulting Fee | $2,748 |
|---|---|
| Food and Beverage | $99.75 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Nov 3, 2025 | Consulting Fee Multiple Therapeutic Areas | $2,748 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $348,607 in research payments for these studies, mostly to the institutions running them.
- 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475 - A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Eli Lilly and Company · Completed · NCT05395481
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.